The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
Open accessAbstract
Introduction: This trial evaluated the safety, biologic activity, and pharmacokinetics of belimumab, a fully human monoclonal antibody that inhibits the biologic activity of the soluble form of the essential B-cell survival factor B-lymphocyte stimulator (BLyS) in patients with systemic lupus erythematosus (SLE). Methods: Seventy patients with mild-to-moderate SLE were enrolled in a phase I, double-blind, randomized study and treated with placebo (n = 13) or belimumab (n = 57) at four different doses (1.0, 4.0, 10, and 20 mg/kg) as a single infusion or two infusions 21 days apart. Patients were followed for 84 to 105 days to assess adverse events, pharmacokinetics, peripheral blood B-cell counts, serology, and SLE disease activity. Data from the study were summarized using descriptive statistics. χ 2 type tests were used to analyze discrete variables. The Kruskal-Wallis test, the Wilcoxon test, and the analysis of covariance were used to analyze the continuous variables, as appropriate. The analysis was performed on all randomized patients who received study agent. Results: The incidences of adverse events and laboratory abnormalities were similar among the belimumab and placebo groups. Belimumab pharmacokinetics were linear across the 1.0 to 20 mg/kg dose range. Long terminal elimination half-life (8.5 to 14.1 days), slow clearance (7 ml/day per kg), and small volume of distribution (69 to 112 ml/kg) were consistent with a fully human antibody. Significant reductions in median percentages of CD20+ B cells were observed in patients treated with a single dose of belimumab versus placebo (day 42: P = 0.0042; and day 84: P = 0.0036) and in patients treated with two doses of belimumab versus placebo (day 105: P = 0.0305). SLE disease activity did not change after one or two doses of belimumab. Conclusions: Belimumab was well tolerated and reduced peripheral B-cell levels in SLE patients. These data support further studies of belimumab in autoimmune disorders. Trial Registration: NCT00657007 [clinicaltrials.gov].
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL
Litinskiy, M. B., Nardelli, B., Hilbert, D. M., He, B., Schaffer, A., Casali, P., & Cerutti, A. (2002) · Nature Immunology · doi:10.1038/ni829 · Cited by 1,252
RetractedHochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations
Mackay, F., Woodcock, S. A., Lawton, P., Ambrose, C., Baetscher, M., Schneider, P., Tschopp, J., & Browning, J. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1697 · Cited by 1,480
The CD40 Antigen and Its Ligand
Banchereau, J., Bazan, F., Blanchard, D., Brière, F., Galizzi, J., van Kooten, C., Liu, Y. J., Rousset, F., & Saeland, S. (1994) · Annual Review of Immunology · doi:10.1146/annurev.immunol.12.1.881 · Cited by 1,263
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
Gross, J. A., Johnston, J., Mudri, S., Enselman, R., Dillon, S. R., Madden, K., Xu, W., Parrish-Novak, J., Foster, D., Lofton-Day, C., et al. (2000) · Nature · doi:10.1038/35010115 · Cited by 1,174
BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator
Moore, P. A., Belvedere, O., Orr, A., Pieri, K., LaFleur, D. W., Feng, P., Soppet, D., Charters, M., Gentz, R., Parmelee, D., et al. (1999) · Science · doi:10.1126/science.285.5425.260 · Cited by 1,144
BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells
O'Connor, B. P., Raman, V. S., Erickson, L. D., Cook, W. J., Weaver, L. K., Ahonen, C., Lin, L.-L., Mantchev, G. T., Bram, R. J., & Noelle, R. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031330 · Cited by 1,128
BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF
Thompson, J. S., Bixler, S. A., Qian, F., Vora, K., Scott, M. L., Cachero, T. G., Hession, C., Schneider, P., Sizing, I. D., Mullen, C., et al. (2001) · Science · doi:10.1126/science.1061965 · Cited by 889
Cheema, G. S., Roschke, V., Hilbert, D. M., & Stohl, W. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1313::aid-art223>3.0.co;2-s · Cited by 802
Self-citationLooney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 776
Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus
Zhang, J., Roschke, V., Baker, K. P., Wang, Z., Alarcón, G. S., Fessler, B. J., Bastian, H., Kimberly, R. P., & Zhou, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.6 · Cited by 734
Buyon, J. P., Petri, M. A., Kim, M. Y., Kalunian, K. C., Grossman, J., Hahn, B. H., Merrill, J. T., Sammaritano, L., Lockshin, M., Alarcón, G. S., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00004 · Cited by 661
Self-citationBoumpas, D. T., Furie, R., Manzi, S., Illei, G. G., Wallace, D. J., Balow, J. E., Vaishnaw, A., & on behalf of the BG9588 Lupus Nephritis Trial Group (2003) · Arthritis & Rheumatism · doi:10.1002/art.10856 · Cited by 618
Self-citationSevere B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice
Khare, S. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050580697 · Cited by 590
Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy
Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.817 · Cited by 543
Stohl, W., Metyas, S., Tan, S., Cheema, G. S., Oamar, B., Xu, D., Roschke, V., Wu, Y., Baker, K. P., & Hilbert, D. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11354 · Cited by 503
Self-citationKayagaki, N., Yan, M., Seshasayee, D., Wang, H., Lee, W., French, D. M., Grewal, I. S., Cochran, A. G., Gordon, N. C., Yin, J., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00425-9 · Cited by 477
Petri, M., Stohl, W., Chatham, W., McCune, W. J., Chevrier, M., Ryel, J., Recta, V., Zhong, J., & Freimuth, W. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23678 · Cited by 428
Self-citationSfikakis, P. P., Boletis, J., Lionaki, S., Vigklis, V., Fragiadaki, K., Iniotaki, A. G., & Moutsopoulos, H. Μ. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20858 · Cited by 410
Yan, M., Brady, J. R., Chan, B., Lee, W. P., Hsu, B., Harless, S., Cancro, M., Grewal, I. S., & Dixit, V. M. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00481-x · Cited by 392
Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R., & Isenberg, D. A. (2005) · Rheumatology · doi:10.1093/rheumatology/kei080 · Cited by 364
Jacobi, A. M., Odendahl, M., Reiter, K., Bruns, A., Burmester, G. R., Radbruch, A., Valet, G., Lipsky, P. E., & Dörner, T. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10949 · Cited by 361
Kalunian, K. C., Davis, J. C., Merrill, J. T., Totoritis, M. C., Wofsy, D., & for the IDEC‐131 Lupus Study Group (2002) · Arthritis & Rheumatism · doi:10.1002/art.10681 · Cited by 336
Self-citationG-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS
Scapini, P., Nardelli, B., Nadali, G., Calzetti, F., Pizzolo, G., Montecucco, C., & Cassatella, M. A. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021343 · Cited by 324
Dörner, T., Kaufmann, J., Wegener, W. A., Teoh, N., Goldenberg, D. M., & Burmester, G. R. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1942 · Cited by 306
Dall'Era, M., Chakravarty, E., Wallace, D., Genovese, M., Weisman, M., Kavanaugh, A., Kalunian, K., Dhar, P., Vincent, E., Pena‐Rossi, C., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23047 · Cited by 294
Classification and definition of major flares in SLE clinical trials
Petri, M., Buyon, J., & Kim, M. (1999) · Lupus · doi:10.1191/096120399680411281 · Cited by 282
The central and multiple roles of B cells in lupus pathogenesis
Chan, O. T. M., Madaio, M. R., Shlomchik, M. J., Chan, O. I. M., Madaio, M. P., & Shlomchik, M. J. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01310.x · Cited by 281
Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity
Yan, M., Marsters, S. A., Grewal, I. S., Wang, H., Ashkenazi, A., & Dixit, V. M. (2000) · Nature Immunology · doi:10.1038/76889 · Cited by 227
Daikh, D. I., Finck, B. K., Linsley, P. S., Hollenbaugh, D., & Wofsy, D. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.7.3104 · Cited by 217
Albert, D., Dunham, J., Khan, S., Stansberry, J., Kolasinski, S., Tsai, D., Pullman-Mooar, S., Barnack, F., Striebich, C., Looney, R. J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083162 · Cited by 209
Kalled, S. L., Cutler, A. H., Datta, S. K., & Thomas, D. W. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.5.2158 · Cited by 199
Cambridge, G., Isenberg, D. A., Edwards, J. C. W., Leandro, M. J., Migone, T.-S., Teodorescu, M., & Stohl, W. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.079418 · Cited by 193
Self-citationVallerskog, T., Heimbürger, M., Gunnarsson, I., Zhou, W., Wahren-Herlenius, M., Trollmo, C., & Malmström, V. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2076 · Cited by 190
Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma
Grillo-Lopez, A., White, C., Dallaire, B., Varns, C., Shen, C., Wei, A., Leonard, J., McClure, A., Weaver, R., Cairelli, S., et al. (2000) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201003379059 · Cited by 176
Halpern, W., Lappin, P. B., Zanardi, T. A., Cai, W., Corcoran, M. L., Zhong, J., & Baker, K. P. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj148 · Cited by 158
Self-citationElevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera
Vakkalanka, R., Woo, C. J., Kirou, K. A., Koshy, M., Berger, D., & Crow, M. K. (1999) · Arthritis & Rheumatism · Cited by 156
Effective B Cell Depletion with Rituximab in the Treatment of Autoimmune Diseases
Kneitz, C. (2002) · Immunobiology · doi:10.1078/0171-2985-00200 · Cited by 140
New approaches of B-cell-directed therapy: beyond rituximab
Dörner, T., & Burmester, G. R. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282f5e08d · Cited by 97
Effects of anti‐CD154 treatment on B cells in murine systemic lupus erythematosus
Wang, X., Huang, W., Schiffer, L. E., Mihara, M., Akkerman, A., Hiromatsu, K., & Davidson, A. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10929 · Cited by 95
B cell depletion therapy in systemic lupus erythematosus
Anolik, J. H., Sanz, I., & Looney, R. J. (2003) · Current Rheumatology Reports · doi:10.1007/s11926-003-0020-x · Cited by 72
A humanized anti-human CD154 monoclonal antibody blocks CD154–CD40 mediated human B cell activation
Brams, P., Black, A., PADLAN, E. A., Hariharan, K., Leonard, J. E., Chambers-Slater, K., Noelle, R. J., & Newman, R. (2001) · International Immunopharmacology · doi:10.1016/s1567-5769(00)00020-5 · Cited by 41
Cited by
Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T., Petri, M. A., Ginzler, E. M., Chatham, W. W., McCune, W. J., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24699 · Cited by 585
Self-citationThe role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Cancro, M. P., D’Cruz, D. P., & Khamashta, M. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38010 · Cited by 283
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Suh, H. Y., Peck, C., Yu, K.-S., & Lee, H. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s121520 · Cited by 51
Oitate, M., Nakayama, S., Ito, T., Kurihara, A., Okudaira, N., & Izumi, T. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-sh-059 · Cited by 35
Metadata
- Authors
- Furie, R., Stohl, W., Ginzler, E. M., Becker, M., Mishra, N., Chatham, W., Merrill, J. T., Weinstein, A., McCune, W. J., Zhong, J., Cai, W., Freimuth, W., & the Belimumab Study Group
- Venue
- Arthritis Research & Therapy
- Published
- 2008-09-11
- Volume
- 10
- Issue
- 5
- Pages
- R109-R109
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2141028706
- Cited by
- 263
- References
- 42
- FWCI
- 19.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.